LADENBURG THALM/SH SH initiated coverage on Helius Medical Technologies
$HSDT
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
LADENBURG THALM/SH SH initiated coverage of Helius Medical Technologies with a rating of Buy
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/15/2021 | Outperform → Market Perform | Noble Capital Markets |
Noble Capital Markets downgraded Helius Medical Tech from Outperform to Market Perform
Noble Capital Markets initiated coverage of Helius Medical with a rating of Outperform and set a new price target of $20.00
LADENBURG THALM/SH SH initiated coverage of Helius Medical Technologies with a rating of Buy
4/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)
4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)
4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)
NEWTOWN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company that has expanded its business to include a digital asset treasury dedicated to acquiring and holding Solana (SOL), today announced that the Company will release its third quarter operating results on Tuesday, November 18, 2025, after market close. Management will host a conference call to discuss the results and provide an expanded business update as follows: Date:Tuesday, November 18, 2025Time:4:30 p.m. Eastern TimeWebcast:Click here The webcast will be archived under the News & Events section of the Company's investor relations website. About Solana Comp
NEWTOWN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company that has expanded its business to include a digital asset treasury dedicated to acquiring and holding Solana (SOL), today announced its plans to tokenize shares of its HSDT fund on Superstate's Opening Bell platform. The initiative marks a major step forward in the Company's strategy to modernize access to capital markets through regulated, onchain infrastructure. Upon launch, shareholders will be able to hold and transfer tokenized representations of HSDT shares on Superstate's Opening Bell, enabling 24/7 trading, real-time settlement, and enhanced global liqu
Invitation-only event features CEOs, investors and innovators across AI, Digital Assets, Fintech and beyond Keynote speakers Michael Saylor and Eric Trump highlight lineup of thought leaders NEW YORK and PALM BEACH, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Clear Street, ("Clear Street", "the Company") a cloud-native financial infrastructure technology firm on a mission to give sophisticated investors access to every asset in every market, will host its Disruptive Technology Conference on November 19–20, 2025, at the Four Seasons Resort Palm Beach, Florida. The two-day, invitation-only event brings together a select group of CEOs, institutional investors and pioneering industry leaders fo
3 - Solana Co (0001610853) (Issuer)
3 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)
4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)
NT 10-Q - Solana Co (0001610853) (Filer)
8-K - Solana Co (0001610853) (Filer)
8-K - Solana Co (0001610853) (Filer)
NEWTOWN, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Today, Solana Company (NASDAQ:HSDT) released the following letter from the Executive Chairman: We are excited to enter the next phase of our lifecycle with a strong capital base and expanded accessibility for investors. This week will be remembered as a foundational moment for Solana Company (NASDAQ:HSDT). We have made the deliberate choice to move forward with our scheduled registration for resale of the shares purchased by investors in the recent private placement rather than delay it. Whereas some of our peers have decided to postpone it at the first sign of market volatility, we want to explain why we made this decision and why we feel
-Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement- -Out of Network reimbursement is only the first step towards expanding third-party paid access to PoNS- NEWTOWN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced an authorized claim for payment for the PoNS Device from a third major healthcare provider, Aetna Healthcare. "The recent reimbursement approvals from two major
NEWTOWN, Pa., May 20, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced it will highlight the results of a new study confirming the therapeutic regimen and sustained efficacy of its Portable Neuromodulation Stimulator (PoNS®) device for people with multiple sclerosis (MS) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting. The event runs from May 28-31 at the Phoenix Convention Center in Phoenix. Deborah Backus, PT, Ph.D., FACRM – Vice President of Research and Innovation at Atlanta's Shepherd Center, one of six sit
NEWTOWN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company that has expanded its business to include a digital asset treasury dedicated to acquiring and holding Solana (SOL), today announced that the Company will release its third quarter operating results on Tuesday, November 18, 2025, after market close. Management will host a conference call to discuss the results and provide an expanded business update as follows: Date:Tuesday, November 18, 2025Time:4:30 p.m. Eastern TimeWebcast:Click here The webcast will be archived under the News & Events section of the Company's investor relations website. About Solana Comp
NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today provided updates on its efforts to achieve fair market access for its Portable Neuromodulation Stimulator (PoNS) device and announced plans to host a business update call today at 9:00am ET. "We disagree with the proposed pricing for the PoNS Mouthpiece and are disappointed CMS has once again mapped the Controller pricing to a code for fundamentally different technology," said Dane Andreeff, Helius' President and Chief Executive Officer. "I
NEWTOWN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its second quarter 2024 financial results on Monday, August 12, 2024, after the market closes. Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer will host a conference call to discuss the results and provide an expanded business update regarding Helius' progress and plans surrounding the U.S. commercialization of PoNS® as follows: Date:Monday, Augus
SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)
SC 13G - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)
SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)